Bioabsorbable Therapeutics, Inc., founded in 2004 and based in Menlo Park, CA, is dedicated to developing and commercializing innovative medical devices for the treatment of coronary and peripheral vascular diseases. The company's core mission is to improve patient outcomes through the use of bioabsorbable technologies. Their flagship products include the Whisper coronary stent system, a balloon-expandable fully absorbable coronary stent, and the Unison Peripheral Stent System, a self-expanding fully absorbable peripheral stent. These devices utilize anti-inflammatory polymers to enhance their bioabsorbable properties.

Notable figures associated with Bioabsorbable Therapeutics include leading experts in cardiovascular medicine and medical device innovation. The company has attracted significant investment from venture capital firms specializing in healthcare and medical technologies. Key achievements include successful clinical trials demonstrating the efficacy and safety of their stents, as well as regulatory approvals that have allowed them to enter various markets. Overall, Bioabsorbable Therapeutics has made a substantial impact on the treatment of vascular diseases by providing advanced, bioabsorbable solutions that reduce long-term complications associated with traditional stents.